Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
alpha-DC1 vaccine and poly-ICLC in recurrent malignant glioma
NCT00766753Phase 2Completed
- Start
- Dec 2006
- Primary completion
- Sep 2009
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of alpha-type-1-polarized dendritic cell vaccine in malignant glioma. Started Dec 2006; status: completed.
02
Drugs
alpha-type-1-polarized dendritic cell vaccine
03
Conditions
malignant glioma
Beyond the preview
Go deeper on NCT00766753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00766753.